Association between triptan use and ischemic events in patients with ischemic risk factors: A meta-analysis.

IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Fahad M Aldehaim, Abdulaziz A Alruways, Abdulaziz A Alfarhan, Saleh N Almunyif, Abdulmajeed Z Alhusainy, Omar H Albahli, Basil A Almutairi, Meshari M Alotaibi, Abdulaziz M Alotaibi, Anas E Alotaibi, Sultan S Aldalbahi, Muhammad Shabbir, Muath A Alammar
{"title":"Association between triptan use and ischemic events in patients with ischemic risk factors: A meta-analysis.","authors":"Fahad M Aldehaim, Abdulaziz A Alruways, Abdulaziz A Alfarhan, Saleh N Almunyif, Abdulmajeed Z Alhusainy, Omar H Albahli, Basil A Almutairi, Meshari M Alotaibi, Abdulaziz M Alotaibi, Anas E Alotaibi, Sultan S Aldalbahi, Muhammad Shabbir, Muath A Alammar","doi":"10.15537/smj.2025.46.6.20250106","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the relationship between ischemic events and triptan use in patients having ischemic risk factors and evaluate the safety profile of these medications in vulnerable individuals.</p><p><strong>Methods: </strong>A detailed search was done using Web of Science, Google Scholar, PubMed, and Medline, up to December 2024. Inclusion criteria encompassed studies focusing on triptan use in individuals having predisposing ischemic risk factors and comparing the incidence of ischemic events between those who use triptans and those who do not. Studies were excluded if they targeted patients without ischemic risk factors, did not assess triptan use, or lacked a comparative analysis between users of triptans and non-users.</p><p><strong>Results: </strong>From an initial pool of 1,615 articles, f4 studies with a total sample size of 426,840 were involved in the study. The analysis revealed no significant statistical relationship between triptan use and ischemic events in patients with ischemic risk factors. Subgroup analysis of Ischemic Stroke (95% CI=0.70-8.78; <i>p</i>=0.16, I<sup>2</sup>=97.7%), Myocardial Infarction (95% CI = 0.44-2.39; <i>p</i>=0.95, I<sup>2</sup>= 96.1%) and All-cause Mortality events (95% CI=0.33-1.58; <i>p</i>=0.44, I<sup>2</sup>=98.8%).</p><p><strong>Conclusion: </strong>Our findings indicate that the use of triptan is not linked to a higher risk of ischemic events, indicating that triptans can be a safe therapeutic option for managing migraines in patients with ischemic risk factors. Nevertheless, Additional research is required to assess the long-term safety of triptans, particularly in high-risk populations. Limitations include the inclusion of only four studies, a limited body of literature available for comparison, and discrepancies in follow-up durations across the included studies.<b>PROSPERO Reg. No.: CRD42024580419</b>.</p>","PeriodicalId":21453,"journal":{"name":"Saudi Medical Journal","volume":"46 6","pages":"608-616"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199639/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15537/smj.2025.46.6.20250106","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To investigate the relationship between ischemic events and triptan use in patients having ischemic risk factors and evaluate the safety profile of these medications in vulnerable individuals.

Methods: A detailed search was done using Web of Science, Google Scholar, PubMed, and Medline, up to December 2024. Inclusion criteria encompassed studies focusing on triptan use in individuals having predisposing ischemic risk factors and comparing the incidence of ischemic events between those who use triptans and those who do not. Studies were excluded if they targeted patients without ischemic risk factors, did not assess triptan use, or lacked a comparative analysis between users of triptans and non-users.

Results: From an initial pool of 1,615 articles, f4 studies with a total sample size of 426,840 were involved in the study. The analysis revealed no significant statistical relationship between triptan use and ischemic events in patients with ischemic risk factors. Subgroup analysis of Ischemic Stroke (95% CI=0.70-8.78; p=0.16, I2=97.7%), Myocardial Infarction (95% CI = 0.44-2.39; p=0.95, I2= 96.1%) and All-cause Mortality events (95% CI=0.33-1.58; p=0.44, I2=98.8%).

Conclusion: Our findings indicate that the use of triptan is not linked to a higher risk of ischemic events, indicating that triptans can be a safe therapeutic option for managing migraines in patients with ischemic risk factors. Nevertheless, Additional research is required to assess the long-term safety of triptans, particularly in high-risk populations. Limitations include the inclusion of only four studies, a limited body of literature available for comparison, and discrepancies in follow-up durations across the included studies.PROSPERO Reg. No.: CRD42024580419.

Abstract Image

Abstract Image

Abstract Image

曲坦类药物使用与缺血性危险因素患者缺血性事件之间的关系:一项荟萃分析。
目的:研究具有缺血性危险因素的患者使用曲坦类药物与缺血性事件之间的关系,并评价这些药物在易感人群中的安全性。方法:详细检索Web of Science,谷歌Scholar, PubMed和Medline,截止到2024年12月。纳入标准包括对有易感缺血性危险因素的个体使用曲坦类药物的研究,并比较使用曲坦类药物和不使用曲坦类药物的人的缺血性事件发生率。如果研究的目标是没有缺血性危险因素的患者,没有评估曲坦类药物的使用,或者缺乏曲坦类药物使用者和非使用者之间的比较分析,则排除研究。结果:从最初的1615篇文章中,有f4篇研究,总样本量为426840。分析显示曲坦类药物的使用与缺血性危险因素患者的缺血性事件之间没有显著的统计学关系。缺血性卒中亚组分析(95% CI=0.70-8.78;p=0.16, I2=97.7%)、心肌梗死(95% CI = 0.44-2.39;p=0.95, I2= 96.1%)和全因死亡事件(95% CI=0.33-1.58;I2 = 98.8%, p = 0.44)。结论:我们的研究结果表明,曲坦类药物的使用与缺血性事件的高风险无关,这表明曲坦类药物可以作为一种安全的治疗选择,用于治疗有缺血性危险因素的偏头痛患者。然而,需要进一步的研究来评估曲坦类药物的长期安全性,特别是在高危人群中。局限性包括仅纳入四项研究,可用于比较的文献有限,以及纳入研究的随访时间存在差异。普洛斯彼罗Reg。否。: CRD42024580419。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Saudi Medical Journal
Saudi Medical Journal 医学-医学:内科
CiteScore
2.30
自引率
6.20%
发文量
203
审稿时长
12 months
期刊介绍: The Saudi Medical Journal is a monthly peer-reviewed medical journal. It is an open access journal, with content released under a Creative Commons attribution-noncommercial license. The journal publishes original research articles, review articles, Systematic Reviews, Case Reports, Brief Communication, Brief Report, Clinical Note, Clinical Image, Editorials, Book Reviews, Correspondence, and Student Corner.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信